Oscillatory positive expiratory pressure (OPEP) devices have been in use as a supplement to traditional chest physiotherapy (CPT) to aid the clearing of respiratory secretions in people who can't cough, especially those with chronic conditions. The use of OPEP devices is still limited in chronic airway disorders such as cystic fibrosis, bronchiectasis, bronchitis, bronchial asthma, and primary ciliary dyskinesia syndrome. In chronic obstructive pulmonary disease (COPD), oscillating positive expiratory pressure (OPEP) devices help with sputum clearance.
The oscillating positive expiratory pressure (OPEP) devices market growth is attributed to the growing prevalence of chronic obstructive pulmonary disease (COPD) and asthma, and advancements in medical technologies. However, low awareness and limited access to OPEP devices hinder the growth of the market.
The incidence of COPD and cystic fibrosis is rising across the world. According to the World Health Organization (WHO), COPD exacerbations are critical events. COPD-related disability and mortality propel the demand for OPEP devices. According to the Center for Disease Control and Prevention (CDC), ~9 million adults were diagnosed with chronic bronchitis in 2018. Also, asthma is becoming common among people of all ages, genders, and races. According to CDC, ~300 million people worldwide suffer from asthma, with the expected addition of 100 million by 2025. The prevalence, severity, and mortality of asthma vary dramatically across the US. Asthma affects more than 25 million people in the US, which equates to 7.7% of adults and 8.4% of children. According to the 2018 Global Asthma Report about Auckland, New Zealand, asthma ranks 16th among the largest causes of disability and 28th among the greatest sources of disease burden, as assessed by disability-adjusted life years. It is common in high-income countries, whereas the majority of asthma-related deaths occur in low- and middle-income countries. Therefore, the rising prevalence of COPD and asthma propels the demand for mucous clearing devices, such as OPEP devices, which bolsters the growth of the oscillating positive expiratory pressure (OPEP) devices market.
The oscillating positive expiratory pressure (OPEP) devices market, based on product, is segmented into mouthpiece PEP devices, face mask PEP devices, and bottle PEP devices. The mouthpiece PEP devices segment held the largest share of the market in 2021. Moreover, it is anticipated to register a CAGR of 5.3% in the market during the forecast period. Mouthpiece PEP helps to remove mucus from the lungs. It can also prevent lung collapse or open up areas that have collapsed. One of the key factors driving the market for mouthpiece PEP devices is the growing elderly population, coupled with higher rates of chronic illnesses such as chronic obstructive pulmonary disease (COPD) and asthma. According to the Centers for Disease Control and Prevention (CDC), ~9 million persons will be diagnosed with chronic bronchitis by 2020, thereby driving the need for mouthpiece devices.
Based on indication, the oscillating positive expiratory pressure (OPEP) devices market is segmented into chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiectasis, cystic fibrosis, and others. The COPD segment held the largest share of the market in 2021. However, the asthma segment is anticipated to register a CAGR of 6.0% during the forecast period. COPD is a common and treatable disease characterized by progressive airflow limitation and tissue destruction. It is associated with structural lung changes due to chronic inflammation from prolonged exposure to noxious particles or gases, most commonly cigarette smoke. Chronic inflammation causes airway narrowing and decreased lung recoil.
Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the oscillating positive expiratory pressure (OPEP) devices market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally. The market is anticipated to flourish in the coming years due to the development of innovative products by market players.
The regional trends and factors influencing the Oscillating Positive Expiratory Pressure (OPEP) Devices Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Oscillating Positive Expiratory Pressure (OPEP) Devices Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 125.66 Million |
| Market Size by 2028 | US$ 179.34 Million |
| Global CAGR (2021 - 2028) | 5.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Oscillating Positive Expiratory Pressure (OPEP) Devices Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Oscillating Positive Expiratory Pressure (OPEP) Devices Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
COVID-19 was more likely to hospitalize those with moderate-to-severe or uncontrolled asthma. The coronavirus can cause pneumonia, blood clots, and acute respiratory distress syndrome, among other lung issues. The epidemic has added new levels of anxiety for both patients and clinicians for the nearly 37 million Americans who live with a chronic lung illness like asthma or chronic obstructive pulmonary disease. Caring for people with COVID-19 and underlying COPD is very difficult at this time. Certain treatments for COPD patients, such as nebulized bronchodilators and non-invasive ventilation (NIV), are thought to enhance the risk of viral transmission via aerosols. Although oscillating positive expiratory pressure (OPEP) devices have been in use with the increasing cases of COVID-19 in the region as studies shows oscillating positive expiratory pressure (OPEP) devices results in minimizing the effect of respiratory distress due to COVID. Also, the Positive Expiratory Pressure (PEP) flute therapy and Positive End-Expiratory Pressure (PEEP) proved to be led to a small yet statistically significant decrease in the severity of respiratory symptoms in adults with COVID-19 recovering at home as per various research studies.
North America held the largest share of the oscillating positive expiratory pressure (OPEP) devices market and is expected to continue its position over the coming years. These oscillating positive expiratory pressure (OPEP) devices are in high demand in North America's regional segment. Furthermore, the presence of a robust medical infrastructure and the early availability of new products and equipment are aiding the area market's overall development.
Trudell Medical International and Allergan Plc are the top two companies that hold huge market shares in the Oscillating Positive Expiratory Pressure (OPEP) Devices market.
The Oscillating Positive Expiratory Pressure (OPEP) Devices market majorly consists of players such as Allergan Plc.; PARI GmbH; Smiths Medical; AirPhysio; D•R BURTON HEALTHCARE; Medica Holdings, LLC; CEGLA Medizintechnik GmbH & Co. KG; Able Healthcare; Trudell Medical International; Mercury Medical amongst others.
The hospital pharmacies segment dominated the global oscillating positive expiratory pressure (OPEP) devices market and accounted for the largest market share of 60.48% in 2021.
The mouthpiece PEP devices segment held the largest share of the market in the global oscillating positive expiratory pressure (OPEP) devices market and held the largest market share of 94.68% in 2021.
The chronic obstructive pulmonary disease (COPD) segment dominated the global oscillating positive expiratory pressure (OPEP) devices market and accounted for the largest market share of 34.60% in 2021.
Oscillatory positive expiratory pressure (OPEP) devices have been used as a supplement to traditional chest physiotherapy (CPT) to aid in the clearing of respiratory secretions in people who can't cough, especially those with chronic conditions. In chronic airway disorders such as cystic fibrosis, bronchiectasis, bronchitis, bronchial asthma, and primary ciliary dyskinesia syndrome, the usage of OPEP devices is still limited. In chronic obstructive pulmonary disease (COPD), oscillating positive expiratory pressure (OPEP) devices are said to help with sputum clearance.
Key factors that are driving the growth of this market are the growing prevalence of chronic obstructive pulmonary disease (COPD) and asthma, and rising technological advancements are expected to boost the market growth for oscillating positive expiratory pressure (OPEP) devices over the years.
The CAGR value of the oscillating positive expiratory pressure (OPEP) devices market during the forecasted period of 2021–2028 is 5.2%.